NICE
Fluocinolone acetonide intravitreal implant for treating chronic DMO after inadequate response to prior therapy
Dec 30
2014
College statement on NICE guidance TA 301 – Fluocinolone acetonide intravitreal implant for treating chronic diabetic macular oedema after inadequate response to prior therapy (rapid review of technology appraisal guidance 271) December 2013
Use of Avastin (bevacizumab) in age related macular degeneration
Dec 30
2014
College statement on the use of Avastin (bevacizumab) in age related macular degeneration December 2014
Statement in response to NICE announcing their positive final guidance for Eylea® for the treatment of macular oedema secondary to CRVO
Dec 30
2014
Statement from The Royal College of Ophthalmologists in response to NICE announcing their positive final guidance for Eylea® for the treatment of macular oedema secondary to CRVO February 2014
Choice of anti VEGF agents for wet AMD treatments
Dec 22
2014
College statement on choice of two antiVEGF agents for the treatment of wet AMD, following NICE guidance on Ranibizumab (TA155) and Aflibercept (TA294). March2014